^
Association details:
Biomarker:FGFR3 S249C
Cancer:Urothelial Cancer
Drug Class:FGFR3 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).

Published date:
02/08/2021
Excerpt:
Seven patients had confirmed activating hotspot FGFR3 mutations (p.S249C or p.Y373C)...3/7 patients with FGFR3 hotspot mutations received an FGFR2/3 inhibitor and none responded…
DOI:
10.1200/JCO.2021.39.6_suppl.472